ANTARES PHARMA, INC. (NASDAQ:ATRS) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition. |
On March 6, 2017, Antares Pharma, Inc. (the Company) updated its
investor presentation, which included preliminary unaudited
operating and financial results for the fourth quarter and year
ended December 31, 2016. The Company reported preliminary total
revenue of $14.2 million and $52.2 million for the quarter and
year ended December 31, 2016, respectively. The Company also
reported a preliminary net loss per share of $0.03 and $0.16 for
the quarter and year ended December 31, 2016, respectively, and a
cash balance of $27.7 million and no debt at December 31, 2016.
The information furnished to Item 2.02 of this Current Report
shall not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, except as shall be expressly set forth by specific
references in such filing.
Item 7.01.Regulation FD Disclosure.
A copy of the Companys updated investor presentation slides that
the Company intends to use effective immediately is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated into this Item 7.01 by reference.
The information disclosed under this Item 7.01, including Exhibit
99.1 hereto, is being furnished and shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, as amended, except as expressly set forth in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Antares Pharma, Inc. Investor Presentation Slides |
About ANTARES PHARMA, INC. (NASDAQ:ATRS)
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector. ANTARES PHARMA, INC. (NASDAQ:ATRS) Recent Trading Information
ANTARES PHARMA, INC. (NASDAQ:ATRS) closed its last trading session 00.00 at 2.50 with 544,378 shares trading hands.
